Chordoma clinical trials
The registry lists 68 studies for Chordoma across more than 10 countries. 15 are recruiting or about to start. 40 of them are mainly about Chordoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.
Get an email when these change. Save the Chordoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Cancer Institute (NCI) (7) · Massachusetts General Hospital (4) · Novartis Pharmaceuticals (3) · Heidelberg University (2) · Harry T Whelan, MD (2) · Xuanwu Hospital, Beijing (2) · M.D. Anderson Cancer Center (2) · Saint John's Cancer Institute (2)
What is being tested here
Drugs under test in Chordoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Palbociclib | 1 | 0 | 2 |
| Zoledronic Acid | 1 | 0 | 1 |
| Pembrolizumab | 1 | 0 | 1 |
| Camrelizumab | 1 | 0 | 1 |
| Apatinib | 1 | 0 | 1 |
| Nivolumab | 0 | 0 | 4 |
| Ipilimumab | 0 | 0 | 2 |
| SHP2 Inhibitor ERAS-601 | 0 | 0 | 2 |
| GI-6301 | 0 | 0 | 2 |
| Imatinib | 0 | 0 | 2 |
Drug classes tested here Immune checkpoint inhibitors 2 open · Tyrosine kinase inhibitors (TKIs) 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 9
- Nov 2026Pembrolizumab and Pemetrexed for Progressive Chordoma · Saint John's Cancer Institute
- Dec 2026Long-Term Longitudinal QoL in Patients Undergoing EEA · Ohio State University
- Dec 2026Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease · Italian Sarcoma Group
- Feb 2027Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors · Susan Chi, MD
- Apr 2027A Study of ERAS-601 in People With Chordoma · Memorial Sloan Kettering Cancer Center
- May 2027Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base · Quironsalud
- Jun 2027A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma · Sichuan Baili Pharmaceutical Co., Ltd.
- Jun 2027High Dose Intensity Modulated Proton Radiation Treatment +/- Surgical Resection of Sarcomas of the Spine, Sacrum and Base of Skull · Massachusetts General Hospital
- Aug 2027Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone · Mayo Clinic
Who these studies take
Of the 12 Chordoma studies recruiting now, 9 (75%) set no upper age limit and 1 (8%) stop at 75 or younger. 3 (25%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (8%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 2 (17%) | 2 (17%) |
| 18 | 11 (92%) | 11 (92%) |
| 30 | 10 (83%) | 10 (83%) |
| 40 | 10 (83%) | 10 (83%) |
| 50 | 11 (92%) | 11 (92%) |
| 65 | 11 (92%) | 11 (92%) |
| 75 | 11 (92%) | 11 (92%) |
| 85 | 9 (75%) | 9 (75%) |
Across all 68 studies, recruiting or not: 19% stop at 75 or younger and 12% at 65; 40% take children; 0% are for women only and 0% for men only; 1% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Results posted1
- Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative CancersOct 20, 2026NCT04416568
Studies
Recruiting first, then most recently updated. Showing 50 of 68. Browse all 68 → or search them.
- Clinical Genetics Branch Eligibility Screening SurveyNot yet recruitingNCT070052971 country
- Children and Adults With ChordomaRecruitingNCT039104651 country
- Exploration of Personalized Biomarkers During Neoadjuvant Radiation Therapy for Spinal and Sacral ChordomaRecruitingNCT064632621 country
- Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid TumorsRecruitingNCT06625190Phase 1/21 country
- Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the BoneRecruitingNCT050332881 country
- BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of BreastAvailableNCT040912951 country
- Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull BaseRecruitingNCT05861245Not applicable1 country
- Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized DiseaseRecruitingNCT02986516Not applicable10 countries
- Pembrolizumab and Pemetrexed for Progressive ChordomaRecruitingNCT06794645Phase 21 country
- Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton TherapyRecruitingNCT06029218Not applicable1 country
- Multi-parametric Imaging in Personalized RadiotherapyRecruitingNCT058880641 country
- Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.RecruitingNCT03242382Phase 21 country
- Apatinib Combined With Camrelizumab in Treating Participants With Advanced ChordomaRecruitingNCT06140732Phase 21 country
- Image Assisted Optimization of Proton Radiation Therapy in Chordomas and ChondrosarcomasRecruitingNCT048326201 country
- Study to Evaluate the Efficacy of Afatinib in Skull Base ChordomaNot yet recruitingNCT05519917Phase 21 country
- Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility GenesActive, not recruitingNCT012006801 country
- High Dose Intensity Modulated Proton Radiation Treatment +/- Surgical Resection of Sarcomas of the Spine, Sacrum and Base of SkullActive, not recruitingNCT01346124Not applicable1 country
- China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial AneurysmActive, not recruitingNCT078091781 country
- Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative CancersActive, not recruitingNCT04416568Phase 21 country
- Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib MesylateCompletedNCT01046487Phase 11 country
- A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid TumorsCompletedNCT04670679Phase 12 countries
- Cetuximab for the Treatment of Advanced Unresectable or Metastatic ChordomaActive, not recruitingNCT05041127Phase 21 country
- Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient TumorsActive, not recruitingNCT05286801Phase 1/23 countries
- Nivolumab and Ipilimumab in Treating Patients With Rare TumorsActive, not recruitingNCT02834013Phase 22 countries
- Proton Beam Therapy for Chordoma PatientsActive, not recruitingNCT00496119Phase 21 country
- Long-Term Longitudinal QoL in Patients Undergoing EEAActive, not recruitingNCT040879021 country
- A Study of ERAS-601 in People With ChordomaActive, not recruitingNCT06957327Phase 1/21 country
- A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic ChordomaActive, not recruitingNCT06787664Phase 21 country
- Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def TumorsActive, not recruitingNCT05407441Phase 1/21 country
- Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic ChordomaActive, not recruitingNCT02989636Phase 11 country
- Nilotinib With Radiation for High Risk ChordomaCompletedNCT01407198Phase 11 country
- Proton Radiation for Chordomas and ChondrosarcomasCompletedNCT01449149Not applicable1 country
- A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.TerminatedNCT02936102Phase 19 countries
- Improvement of Local Control in Skull Base, Spine and Sacral Chordomas Treated by Surgery and Protontherapy Targeting Hypoxic Cells Revealed by [18F]FAZA) PET/CT TracersCompletedNCT02802969Phase 21 country
- Descriptive Cohort of French Patients Treated With Carbonetherapy Since October 2010 Outside PHRC-ETOILECompletedNCT065359971 country
- TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing CancerCompletedNCT04246671Phase 11 country
- QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.WithdrawnNCT03647423Phase 1/21 country
- Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain CancersCompletedNCT03190174Phase 1/21 country
- Afatinib in Locally Advanced and Metastatic ChordomaCompletedNCT03083678Phase 23 countries
- A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null TumorsTerminatedNCT05355753Phase 11 country
- QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine ChordomaCompletedNCT02383498Phase 21 country
- Nivolumab and Relatlimab in Treating Participants With Advanced ChordomaCompletedNCT03623854Phase 21 country
- Ion Irradiation of Sacrococcygeal ChordomaActive, not recruitingNCT01811394Phase 21 country
- Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue SarcomaCompletedNCT009192697 countries
- A Prospective Study of Surgical Treatment Strategies for ChordomaStatus unknownNCT05707767Not applicable1 country
- BN Brachyury and Radiation in ChordomaCompletedNCT03595228Phase 21 country
- CDK4/6 Inhibition in Locally Advanced/Metastatic ChordomaCompletedNCT03110744Phase 21 country
- Pemetrexed for the Treatment of ChordomaCompletedNCT03955042Phase 11 country
- A Study of IMRT in Primary Bone and Soft Tissue SarcomaCompletedNCT02520128Not applicable2 countries
- Immunohistochemical Study of Chordomas to Improve Their Diagnosis and Prognosis CareCompletedNCT044868201 country